Stefan Zielonka

Associate Director at Merck KGaA

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. At the moment, he works as Associate Director at Merck Healthcare KGaA (EMD Serono), Germany, in the Department Protein Engineering and Antibody Technologies (PEAT).


Title: Affinity maturation of B7-H6 translates into enhanced NK cell-mediated tumor cell lysis and improved proinflammatory cytokine release of bispecific immunoligands via NKp30 engagement